FDA Signals New Testosterone Pathway - Takeaway - MDSpire

FDA Signals New Testosterone Pathway

Share

  • 1

    The FDA is encouraging sponsors of testosterone replacement therapy to pursue a new indication for low libido in men with idiopathic hypogonadism.

  • 2

    Currently, TRT products are approved only for men with hypogonadism due to established structural or genetic causes.

  • 3

    The FDA's review indicated that TRT may be safe and effective for men with decreased libido linked to idiopathic hypogonadism.

  • 4

    Sponsors are advised to contact the FDA by April 30 to discuss submission requirements for supplemental applications.

  • 5

    Any new indication approval will require substantial evidence of effectiveness and a favorable risk-benefit assessment.

Original Source(s)

FDA Signals New Testosterone Pathway

  • by Kathryn Wighton

  • April 16, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Spectroscopy Roundup: Rover Dogs and Raman Vision

Semi-autonomous robots showcase the future of planetary exploration, as spectroscopy also reshapes lab-on-chip biology and microplastics research

  • April 14, 2026

  • 5 min
FDA Flags Missing Trial Results

Federal outreach seeks to improve compliance with ClinicalTrials.gov reporting requirements and make more complete clinical trial information publicly available